번역 진행 중 — 귀하의 언어 버전을 준비하는 동안 이 콘텐츠가 영어로 표시됩니다.

토론으로 돌아가기

로그인하여 저장하고 업데이트를 받으세요.

Variations in Incidence and Financial Burdens of Nonpancreatic Postendoscopic Retrograde Cholangiopancreatography Adverse Events

Healthcare

United States

July 18, 2026에 시작됨

Nonpancreatic ERCP adverse events occur in over 5% of cases and can impose a substantial financial burden on both healthcare systems and patients

출처 기사

Variations in Incidence and Financial Burdens of Nonpancreatic Postendoscopic Retrograde Cholangiopancreatography Adverse Events

RAND Corporation (United States) | Jul 16, 2026

진술 추가 분석 0/5

정렬 기준:

Need to find a specific claim? Search all statements.

🗳️ Join the conversation

10 투표할 진술 • Your perspective shapes the analysis

📊 Progress to Consensus Analysis Need: 7+ participants, 20+ votes, 3+ votes per statement

Participants 0/7

Statements (10+ recommended) 10/10

Total Votes 0/20

💡 Progress updates live here. Final readiness is confirmed when all three requirements are met.

Your votes count

No account needed — your votes are saved and included in the consensus analysis. Create an account to track your voting history and add statements.

CLAIM 게시자: admin • Jul 18, 2026

Data on ERCP complication costs should be collected and analysed systematically so healthcare decisions are based on evidence, not assumptions.

번역 대기 중

💬 토론 보기

Be first to respond

Vote to see results

CLAIM 게시자: admin • Jul 18, 2026

Healthcare providers should implement more robust protocols to minimize nonpancreatic ERCP adverse events.

번역 대기 중

💬 토론 보기

Be first to respond

Vote to see results

CLAIM 게시자: admin • Jul 18, 2026

ERCP procedures carry inherent risks that cannot be eliminated, so patients must accept financial responsibility for some complication costs as part of informed consent.

번역 대기 중

💬 토론 보기

Be first to respond

Vote to see results

CLAIM 게시자: admin • Jul 18, 2026

The financial burden of nonpancreatic ERCP adverse events should not be solely borne by patients.

번역 대기 중

💬 토론 보기

Be first to respond

Vote to see results

CLAIM 게시자: admin • Jul 18, 2026

Nonpancreatic ERCP adverse events should be more prominently addressed in medical training programs.

번역 대기 중

💬 토론 보기

Be first to respond

Vote to see results

CLAIM 게시자: admin • Jul 18, 2026

Whether adverse event rates vary by patient demographics or provider experience, payers should fund prospective tracking systems to identify cost drivers.

번역 대기 중

💬 토론 보기

Be first to respond

Vote to see results

CLAIM 게시자: admin • Jul 18, 2026

Healthcare systems must prioritize funding for research on nonpancreatic ERCP adverse events.

번역 대기 중

💬 토론 보기

Be first to respond

Vote to see results

CLAIM 게시자: admin • Jul 18, 2026

Nonpancreatic ERCP adverse events are a necessary risk that patients must accept for the potential benefits of the procedure.

번역 대기 중

💬 토론 보기

Be first to respond

Vote to see results

CLAIM 게시자: admin • Jul 18, 2026

Medical centres should benchmark their ERCP safety performance against peers and share best practices to lower complication rates across all providers.

번역 대기 중

💬 토론 보기

Be first to respond

Vote to see results

CLAIM 게시자: admin • Jul 18, 2026

Insurance companies should deny payment for ERCP-related complications if the procedure was performed at a hospital with above-average adverse event rates.

번역 대기 중

💬 토론 보기

Be first to respond

Vote to see results

💡 How This Works

• Add Statements: Post claims or questions (10-500 characters)
• Vote: Agree, Disagree, or Unsure on each statement
• Respond: Add detailed pro/con responses with evidence
• Consensus: After enough participation, analysis reveals opinion groups and areas of agreement

Society Speaks is open and independent. Your support keeps civic discussion free from advertising and commercial influence.